SAGA DIAGNOSTICS

Pathlight™
Molecular Residual Disease

# A guiding light in early cancer detection

The next generation of molecular residual disease detection and cancer monitoring



# What is Molecular Residual Disease (MRD) testing?

## MRD testing is a cancer surveillance (cancer monitoring) method that uses routine blood draws to detect tiny fragments of tumor-specific DNA.

Many tumors shed tiny fragments of DNA into the bloodstream. This circulating tumor DNA (ctDNA) is unique to each person's tumor, similar to a fingerprint. Pathlight is a first-of-its-kind, multi-cancer MRD test based on your tumor's unique molecular fingerprint. The test can be conducted many times over the course of your care to track how your cancer is responding to treatments, allowing for continuous cancer surveillance.

# Why is cancer surveillance important?

## Cancer surveillance is important because it can offer you and your clinician insight into whether your cancer has recurred and whether your treatment is working before you have symptoms, or before it can be detected by standard-of-care imaging.

Cancer surveillance helps your doctor answer important questions about your cancer that inform your care. The results from an MRD test can help your doctor decide how best to treat your cancer, whether a treatment is working effectively, or whether there are still trace amounts of cancer in your body after treatment. Pathlight is ultra sensitive, so it can detect small amounts of cancer much earlier than other surveillance methods, including imaging tools like computerized tomography (CT) scan, magnetic resonance imaging (MRI), positron emission tomography (PET) scan, and mammography.

# How is MRD testing performed?

MRD testing involves the initial development of a personalized molecular fingerprint using a tissue biopsy sample, and thereafter periodic blood draws for cancer monitoring.

**Personalized test development** After diagnosis, a sample of your tumor tissue is used to develop your personalized MRD test, based on your tumor's "fingerprint" – genetic characteristics that make your tumor cells unique from your healthy cells.

**Routine blood testing** After a routine blood draw, your sample will be checked for your tumor's ctDNA using your personalized MRD test.

**Results** Pathlight may detect the presence or absence of ctDNA each time it is ordered.

# How long will it take to receive my results?

**Personalized test development**

**3-4 weeks** to develop your personalized tumor fingerprint test and initial MRD blood test following receipt of both tissue and blood at the laboratory

**Routine blood tests**

**3-5 days** to receive the results of your blood test following receipt of blood at the laboratory

# Test Results

Your test results track whether your cancer has recurred and can provide insights into how your cancer is responding to treatment over time.


ctDNA **detected**

DNA from your tumor was detected in your blood, meaning some amount of cancer is still present

ctDNA **not detected**

There is no evidence for residual cancer at this time

Amount of ctDNA is **increasing** over time

This may be an early indication that your cancer is recurring, or resisting treatment†

Amount of ctDNA is **decreasing** over time

If your tests are positive, but the amount of ctDNA detected in your blood is decreasing over time, it may indicate your cancer is responding to treatment†

† for informational purposes only

# How accurate is Pathlight?

**Pathlight is highly accurate, with true positive and true negative rates of 100% in its first pivotal study.**

Pathlight uses a new "molecular fingerprinting" method that can detect the absence or presence of ctDNA in blood. This means that you can be confident in your results.[1]



Learn more about Pathlight

## Affordable pricing and billing options

The total cost of the Pathlight test can vary depending on your insurance coverage, clinical diagnosis, and any applicable copays or deductibles. We will work with your healthcare provider and insurance plan to determine your expected out-of-pocket cost before the test is performed. If you're uninsured or underinsured, you may qualify for our Patient Support Program.

You can learn more about our affordable pricing and billing options on our website. You can also contact our Billing support line at 1-919-371-0283 or email us at billing@sagadiagnostics.com.

## References


1. Elliott MJ, Howarth K, Main S, et al. Ultrasensitive detection and monitoring of circulating tumor DNA using structural variants in early-stage breast cancer. *Clin Cancer Res*. Published online January 7, 2025. doi:10.1158/1078-0432.CCR-24-3472


SAGA® DIAGNOSTICS

Pathlight™ Molecular Residual Disease


860 Aviation Parkway, Suite 300 | Morrisville, NC 27560 | sagadiagnostics.com
Email: clientservices@sagadiagnostics.com | Phone: +1 919 371 0283 | Fax: +1 919 371 0262 | Toll free: 866 226 2611


BR-PAT-20250523-v1.0